title: Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine.
abstract: Hyperhomocysteinemia is considered to be a risk factor for vascular diseases including ischemic stroke. It has been shown that plasma homocysteine level can be lowered by folic acid supplementation. Vitamin B(12) may be also beneficial when included in the supplement regimen with folic acid. We have examined in Japanese patients with ischemic stroke the homocysteine-lowering potential of a combination therapy with folic acid and vitamin B(12). Patients with ischemic stroke were randomized into three groups and each group received vitamin B(12) (1500 microg/day, n = 63), folic acid (5 mg/day, n = 64), or both vitamin B(12) and folic acid (n = 64) for 8 weeks. Plasma levels of homocysteine and these vitamins were followed. Significant reduction in plasma homocysteine was observed in all three groups, and the combination therapy yielded the most remarkable result, i.e., plasma total homocysteine was reduced by 38.5% and this was significantly larger than the reduction in other two groups (22.4% and 10.9% in the groups received folic acid and vitamin B(12), respectively). Vitamin B(12) synergizes with folic acid in reducing plasma homocysteine in Japanese patients with ischemic stroke and the combined therapy may be particularly effective in the secondary prevention.
authors.affiliation: Department of Neurology, Kurume University Medical Center, Kurume 839-0863, Japan. noukenrs@cc.hirosaki-u.ac.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Sato
authors.forename: Masahide
authors.initials: M
authors.lastname: Kaji
authors.forename: Izumi
authors.initials: I
authors.lastname: Kondo
authors.forename: Hidemi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Kei
authors.initials: K
authors.lastname: Satoh
authors.forename: Norifumi
authors.initials: N
authors.lastname: Metoki
mesh_terms: D000368:Aged; D002908:Chronic Disease; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005492:Folic Acid / Q000097:blood / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006711:Homocystine / Q000097:blood / Q000187:drug effects; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000188:drug therapy*; D007564:Japan; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*
chemical_list: D006397:Hematinics; D006711:Homocystine; D005492:Folic Acid; C019476:mecobalamin; D014805:Vitamin B 12